DE10152469A1 - 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung - Google Patents

3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Info

Publication number
DE10152469A1
DE10152469A1 DE10152469A DE10152469A DE10152469A1 DE 10152469 A1 DE10152469 A1 DE 10152469A1 DE 10152469 A DE10152469 A DE 10152469A DE 10152469 A DE10152469 A DE 10152469A DE 10152469 A1 DE10152469 A1 DE 10152469A1
Authority
DE
Germany
Prior art keywords
ethyl
dimethylamino
phenol
methyl
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10152469A
Other languages
German (de)
English (en)
Inventor
Johannes Bartholomaeus
Iris Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE10152469A priority Critical patent/DE10152469A1/de
Priority to PE2002001030A priority patent/PE20030527A1/es
Priority to PL369756A priority patent/PL216535B1/pl
Priority to DE50204198T priority patent/DE50204198D1/de
Priority to RU2004116066/15A priority patent/RU2325905C2/ru
Priority to BRPI0213653A priority patent/BRPI0213653B8/pt
Priority to SI200230224T priority patent/SI1439829T1/sl
Priority to NZ532999A priority patent/NZ532999A/en
Priority to IL16158702A priority patent/IL161587A0/xx
Priority to CA2739611A priority patent/CA2739611C/fr
Priority to CNB028259769A priority patent/CN100402021C/zh
Priority to JP2003537620A priority patent/JP4758064B2/ja
Priority to KR1020047006113A priority patent/KR100958045B1/ko
Priority to EP02781278A priority patent/EP1439829B1/fr
Priority to DK02781278T priority patent/DK1439829T3/da
Priority to PT02781278T priority patent/PT1439829E/pt
Priority to AU2002349001A priority patent/AU2002349001C1/en
Priority to PCT/EP2002/011806 priority patent/WO2003035054A1/fr
Priority to ES02781278T priority patent/ES2248622T3/es
Priority to MXPA04003742A priority patent/MXPA04003742A/es
Priority to AT02781278T priority patent/ATE303802T1/de
Priority to CA2464578A priority patent/CA2464578C/fr
Priority to PCT/EP2002/011809 priority patent/WO2003035053A1/fr
Priority to HU0402104A priority patent/HU230161B1/hu
Priority to ARP020104010A priority patent/AR036943A1/es
Priority to MYPI20023979A priority patent/MY127797A/en
Publication of DE10152469A1 publication Critical patent/DE10152469A1/de
Priority to CO04037005A priority patent/CO5570662A2/es
Priority to IL161587A priority patent/IL161587A/en
Priority to US10/831,368 priority patent/US20050058706A1/en
Priority to NO20041924A priority patent/NO331896B1/no
Priority to EC2004005102A priority patent/ECSP045102A/es
Priority to ZA2004/03928A priority patent/ZA200403928B/en
Priority to HK05100703A priority patent/HK1068539A1/xx
Priority to JP2010176084A priority patent/JP2010280697A/ja
Priority to US13/242,800 priority patent/US20120034304A1/en
Priority to NO2012007C priority patent/NO2012007I2/no
Priority to CY2012022C priority patent/CY2012022I2/el
Priority to US13/868,635 priority patent/US20130237608A1/en
Priority to US15/018,529 priority patent/US20160151309A1/en
Priority to ARP160101684A priority patent/AR104921A2/es
Priority to US15/377,628 priority patent/US20170087103A1/en
Priority to US15/943,175 priority patent/US20180221308A1/en
Priority to US16/600,974 priority patent/US11007156B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE10152469A 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung Withdrawn DE10152469A1 (de)

Priority Applications (43)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
PE2002001030A PE20030527A1 (es) 2001-10-24 2002-10-18 Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2464578A CA2464578C (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
HU0402104A HU230161B1 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
RU2004116066/15A RU2325905C2 (ru) 2001-10-24 2002-10-22 Содержащее 3-(3-диметиламино-1-этил-2-метилпропил)фенол лекарственное средство с замедленным высвобождением действующего вещества
DE50204198T DE50204198D1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
SI200230224T SI1439829T1 (sl) 2001-10-24 2002-10-22 Zdravilo, ki vsebuje 3-(3-dimetilamino-1-etil-2-metil-propil)fenol, z zapoznelim sproscanjem aktivne snovi
NZ532999A NZ532999A (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
IL16158702A IL161587A0 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
CA2739611A CA2739611C (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
CNB028259769A CN100402021C (zh) 2001-10-24 2002-10-22 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
JP2003537620A JP4758064B2 (ja) 2001-10-24 2002-10-22 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
KR1020047006113A KR100958045B1 (ko) 2001-10-24 2002-10-22 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)페놀을 함유하고활성 성분의 방출이 지연되는 약제
EP02781278A EP1439829B1 (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
DK02781278T DK1439829T3 (da) 2001-10-24 2002-10-22 Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof
PT02781278T PT1439829E (pt) 2001-10-24 2002-10-22 Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
AU2002349001A AU2002349001C1 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
PCT/EP2002/011809 WO2003035053A1 (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
ES02781278T ES2248622T3 (es) 2001-10-24 2002-10-22 Medicamento que contiene 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y que proporciona una liberacion retardada del principio activo.
MXPA04003742A MXPA04003742A (es) 2001-10-24 2002-10-22 Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.
AT02781278T ATE303802T1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phen l enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
PL369756A PL216535B1 (pl) 2001-10-24 2002-10-22 Preparat farmaceutyczny oraz tabletka
PCT/EP2002/011806 WO2003035054A1 (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
BRPI0213653A BRPI0213653B8 (pt) 2001-10-24 2002-10-22 formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo
ARP020104010A AR036943A1 (es) 2001-10-24 2002-10-23 Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
MYPI20023979A MY127797A (en) 2001-10-24 2002-10-24 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient
CO04037005A CO5570662A2 (es) 2001-10-24 2004-04-22 Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
IL161587A IL161587A (en) 2001-10-24 2004-04-22 Pharmaceutical composition containing 3 - (3 - dimethylamino - 1 - ethyl - 2 - methyl - propyl) phenol and providing delayed release of the active ingredient
US10/831,368 US20050058706A1 (en) 2001-10-24 2004-04-26 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
NO20041924A NO331896B1 (no) 2001-10-24 2004-05-11 Farmasoytisk preparat med forsinket frigivelse inneholdende 3-(3-dimetylamino-1 etyl-2-metyl-propyl)fenol
EC2004005102A ECSP045102A (es) 2001-10-24 2004-05-12 Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
ZA2004/03928A ZA200403928B (en) 2001-10-24 2004-05-20 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HK05100703A HK1068539A1 (en) 2001-10-24 2005-01-27 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
JP2010176084A JP2010280697A (ja) 2001-10-24 2010-08-05 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
US13/242,800 US20120034304A1 (en) 2001-10-24 2011-09-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
NO2012007C NO2012007I2 (no) 2001-10-24 2012-05-08 Tapentadol (1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)fenol eller et farmasøytisk godtakbart salt derav
CY2012022C CY2012022I2 (el) 2001-10-24 2012-08-13 Φαρμακο που περιεχει 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)φαινολη με επιβραδυμενη απελευθερωση δραστικης ουσιας
US13/868,635 US20130237608A1 (en) 2001-10-24 2013-04-23 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
US15/018,529 US20160151309A1 (en) 2001-10-24 2016-02-08 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
ARP160101684A AR104921A2 (es) 2001-10-24 2016-06-07 Formulación farmacéutica con liberación retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmacéuticamente aceptable del mismo y tabletas para administración oral, que la contienen
US15/377,628 US20170087103A1 (en) 2001-10-24 2016-12-13 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US15/943,175 US20180221308A1 (en) 2001-10-24 2018-04-02 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US16/600,974 US11007156B2 (en) 2001-10-24 2019-10-14 Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
DE10152469A1 true DE10152469A1 (de) 2003-06-26

Family

ID=7703560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10152469A Withdrawn DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Country Status (4)

Country Link
AR (1) AR104921A2 (fr)
CA (1) CA2739611C (fr)
DE (1) DE10152469A1 (fr)
RU (1) RU2325905C2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185804A1 (fr) 2020-03-16 2021-09-23 Grünenthal GmbH Comprimé sécable

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2352494T3 (pl) * 2008-10-30 2020-03-31 Grünenthal GmbH Nowe i silne postaci dawkowania tapentadolu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185804A1 (fr) 2020-03-16 2021-09-23 Grünenthal GmbH Comprimé sécable

Also Published As

Publication number Publication date
RU2325905C2 (ru) 2008-06-10
RU2004116066A (ru) 2005-05-10
AR104921A2 (es) 2017-08-23
CA2739611A1 (fr) 2003-05-01
CA2739611C (fr) 2013-12-10

Similar Documents

Publication Publication Date Title
EP1439829B1 (fr) Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
EP0642788B1 (fr) Médicaments contenant de sel de tramadol avec une libération retardée d'ingrédient actif
DE60021749T2 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE69826113T2 (de) R- und s- enantiomere getrennteteile enthaltende dosierungsformen
EP2057984B1 (fr) Comprimé à effet différé contenant de l'hydromorphone
EP1372624B1 (fr) Medicament a base de tramadol
DE102005016981A1 (de) Kombination zur Therapie bei benigner Prostatahyperplasie
DE102005054610B4 (de) Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
DE112011101605T5 (de) Pharmazeutische Zusammensetzung umfassend Hydromorphon und Naloxon
WO2010043408A2 (fr) Fésotérodine microencapsulée
EP1113787A1 (fr) Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
DE602004006443T2 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
DE69817848T2 (de) Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
WO2005009329A2 (fr) Medicament a base de 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol caracterise par une liberation differee du principe actif
DE102009033621A1 (de) Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2314286A1 (fr) Cinacalcet en granulés à fondre
EP0914823A1 (fr) Préparation orale à effet retard comprenant Tramadol et son procédé de fabrication
EP1928441B1 (fr) Formulation à effet retard comprenant du 3-(2-diméthyleaminométhylecyclohexyle)phenol
DE4315525B4 (de) Pharmazeutische Zusammensetzung
DE69914472T2 (de) Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung
DE10152469A1 (de) 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE102013009114A1 (de) Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
DE10248309A1 (de) 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
EP1507519B1 (fr) Medicament contenant du 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol, liberant le principe actif de maniere retardee
WO2009135623A1 (fr) Médicament à la galanthamine avec libération contrôlée

Legal Events

Date Code Title Description
OR8 Request for search as to paragraph 43 lit. 1 sentence 1 patent law
8105 Search report available
8141 Disposal/no request for examination